Pfizer trims expectations for 2023 with sales of COVID-19 vaccine, treatment, weaker than thought
Shares of Pfizer are falling before the opening bell as the company cut its full-year outlook, citing declining sales of its COVID-19-related products.
Watch CBS News
Shares of Pfizer are falling before the opening bell as the company cut its full-year outlook, citing declining sales of its COVID-19-related products.
The world's first ever RSV vaccine for adults could soon be available.
The world's first ever RSV vaccine for adults could soon be available.
Recent small studies, not yet peer-reviewed, suggested the new boosters may not be significantly better than the original vaccine formula.
The federal budget for buying and distributing COVID-19 vaccines will run out "as early as January."
